Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis Noel W. Clarke  European Urology Supplements  Volume 5, Issue 17, Pages 873-876 (October 2006) DOI: 10.1016/j.eursup.2006.07.019 Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 1 Bone loss is accelerated with androgen-deprivation therapy (ADT). Data from Kanis et al. [4] and Maillefert et al. [1]. European Urology Supplements 2006 5, 873-876DOI: (10.1016/j.eursup.2006.07.019) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 2 Relative risk of fracture among men with prostate cancer. ADT=androgen-deprivation therapy; PC=prostate cancer; GnRH=gonadotropin-releasing hormone. Data from Smith et al. [9]. European Urology Supplements 2006 5, 873-876DOI: (10.1016/j.eursup.2006.07.019) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 3 Fractures negatively correlate with survival in patients with prostate cancer. Adapted with permission from Oefelein et al. [12]. European Urology Supplements 2006 5, 873-876DOI: (10.1016/j.eursup.2006.07.019) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 4 Communicating the results of the bone mineral density (BMD) test [17–20]. European Urology Supplements 2006 5, 873-876DOI: (10.1016/j.eursup.2006.07.019) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 5 Identifying and treating bone loss in men with prostate cancer. ADT=androgen-deprivation therapy; BMD=bone mineral density; CT=computed tomography; DEXA=dual-energy x-ray absorptiometry. Adapted with permission from Diamond et al. [16]. European Urology Supplements 2006 5, 873-876DOI: (10.1016/j.eursup.2006.07.019) Copyright © 2006 European Association of Urology Terms and Conditions